Use of amphotericin B as lipid emulsions to decrease its toxicity in critical patients

Simple item page
dc.catalogadorjwg
dc.contributor.authorHernández P., G.
dc.contributor.authorAltermatt Couratier, Fernando René
dc.contributor.authorBernucci P., F.
dc.contributor.authorAcuña C., D.
dc.contributor.authorApablaza E., F.
dc.contributor.authorValenzuela P., F.
dc.contributor.authorLefio C., A.
dc.contributor.authorPérez C., C.
dc.contributor.authorBugedo T., G.
dc.contributor.authorCastillo F., L.
dc.date.accessioned2024-08-23T20:32:41Z
dc.date.available2024-08-23T20:32:41Z
dc.date.issued2000
dc.description.abstractBackground: Amphotericin D is efficacious for the treatment of systemic candidiasis, however it has potentially serious toxic effects. Administration as lipid emulsions has been advocated to decrease its toxicity. Aim: To compare the safety and tolerance of amphotericin B administered as lipid emulsion or dissolved in dextrose in water. Patients and methods: Forty five patients with confirmed or highly suspected systemic candidiasis were studied. Between January 1996 and June 1997 amphotericin B was administered in dextrose in water to 17patients (group 1). Between July 1997 and December 1998, the drug was delivered in lipid emulsions (Intralipid, group 2). Clinical and laboratory parameters (serum creatinine, urea nitrogen and potassium), were assessed daily. Results: Both treatment groups were clinically comparable and had the same survival. Accumulative amphotericin B dose administered was 343.2 ± 197 and 414.6 ± 518 mg respectively. Hypokalemia was more frequent in group 2 (52 and 25 % respectively, p < 0.05). There were no differences in the outcome of renal function or other adverse reactions. Conclusions: Administration of amphotericin B as lipid emulsions did not reduce its toxicity in critical patients.
dc.format.extent7 páginas
dc.fuente.origenORCID
dc.identifier.issn0034-9887
dc.identifier.pubmedidMEDLINE:11349508
dc.identifier.urihttp://www.scopus.com/inward/record.url?eid=2-s2.0-0034305682&partnerID=MN8TOARS
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/87660
dc.information.autorucEscuela de Medicina; Altermatt Couratier, Fernando Rene; 0000-0002-0464-8643; 7381
dc.issue.numero10
dc.language.isoen
dc.nota.accesocontenido completo
dc.pagina.final1107
dc.pagina.inicio1101
dc.publisherSociedad Médica de Santiago
dc.relation.ispartofEuropean Congress on Intensive Care Medicine : XII : 1999 : Berlin, Germany
dc.revistaRevista Médica de Chile
dc.rightsacceso restringido
dc.subjectadverse effects
dc.subjectamphotericin B
dc.subjectantibiotics,
dc.subjectantifungal
dc.subjectdrug toxicity
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.titleUse of amphotericin B as lipid emulsions to decrease its toxicity in critical patients
dc.title.alternativeUso de anfotericina B en mezcla lipídica: ¿Previene la toxicidad de la droga en pacientes críticos?
dc.typeartículo
dc.volumen128
sipa.codpersvinculados7381
sipa.trazabilidadORCID;2024-08-19
sipa.trazabilidadScopus;12-10-2021
Files
Collections
Artículos de revistas